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Summary 
Background 
Few effective treatments exist for patients with refractory or relapsed and refractory multiple 
myeloma not responding to treatment with bortezomib and lenalidomide. Pomalidomide alone has 
shown limited efficacy in patients with relapsed multiple myeloma, but synergistic effects have 
been noted when combined with dexamethasone. We compared the efficacy and safety of 
pomalidomide plus low-dose dexamethasone with high-dose dexamethasone alone in these patients. 
Methods 
This multicentre, open-label, randomised phase 3 trial was undertaken in Australia, Canada, 
Europe, Russia, and the USA. Patients were eligible if they had been diagnosed with refractory or 
relapsed and refractory multiple myeloma, and had failed at least two previous treatments of 
bortezomib and lenalidomide. They were assigned in a 2:1 ratio with a validated interactive voice 
and internet response system to either 28 day cycles of pomalidomide (4 mg/day on days 1–21, 
orally) plus low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22, orally) or high-dose 
dexamethasone (40 mg/day on days 1–4, 9–12, and 17–20, orally) until disease progression or 
unacceptable toxicity. Stratification factors were age (≤75 years vs >75 years), disease population 
(refractory vs relapsed and refractory vs bortezomib intolerant), and number of previous treatments 
(two vs more than two). The primary endpoint was progression-free survival (PFS). Analysis was 
by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01311687, and 
with EudraCT, number 2010-019820-30. 
Findings 
The accrual for the study has been completed and the analyses are presented. 302 patients were 
randomly assigned to receive pomalidomide plus low-dose dexamethasone and 153 high-dose 
dexamethasone. After a median follow-up of 10·0 months (IQR 7·2–13·2), median PFS with 
pomalidomide plus low-dose dexamethasone was 4·0 months (95% CI 3·6–4·7) versus 1·9 months 
(1·9–2·2) with high-dose dexamethasone (hazard ratio 0·48 [95% CI 0·39–0·60]; p<0·0001). The 
most common grade 3–4 haematological adverse events in the pomalidomide plus low-dose 
dexamethasone and high-dose dexamethasone groups were neutropenia (143 [48%] of 300 vs 24 
[16%] of 150, respectively), anaemia (99 [33%] vs 55 [37%], respectively), and thrombocytopenia 
(67 [22%] vs 39 [26%], respectively). Grade 3–4 non-haematological adverse events in the 
pomalidomide plus low-dose dexamethasone and high-dose dexamethasone groups included 
pneumonia (38 [13%] vs 12 [8%], respectively), bone pain (21 [7%] vs seven [5%], respectively), 
and fatigue (16 [5%] vs nine [6%], respectively). There were 11 (4%) treatment-related adverse 
events leading to death in the pomalidomide plus low-dose dexamethasone group and seven (5%) in 
the high-dose dexamethasone group. 
Interpretation 
Pomalidomide plus low-dose dexamethasone, an oral regimen, could be considered a new treatment 
option in patients with refractory or relapsed and refractory multiple myeloma. 
Funding 
Celgene Corporation. 
 
Introduction 
The prognosis for patients with multiple myeloma who are refractory to proteasome inhibitors such 
as bortezomib, and to immunomodulatory drugs such as lenalidomide is poor: with further 
treatment, median overall survival is 9 months, and 3 months without further treatment.
1
 There are 
few treatment options, with corticosteroids alone or combined with other drugs being the most 
commonly used.
1
 
Lenalidomide and pomalidomide have direct antimyeloma, immunomodulatory, and stromal-cell 
effects.
2
 Unlike lenalidomide, of which about 82% is excreted as the parent drug in the urine, 2% of 
pomalidomide is excreted unchanged through the kidneys. The results of an ongoing phase 1 study 
should confirm the dose of pomalidomide to be used in patients with renal impairment.
3
 
Pomalidomide has limited activity as monotherapy in patients with relapsed multiple myeloma,
4 and 5
 
but has synergistic effects when used in combination with dexamethasone.
6, 7 and 8
 This combination 
has shown clinical efficacy in patients with multiple myeloma who had been treated with 
bortezomib or lenalidomide, or both, with 25–35% of patients in phase 2 studies achieving a partial 
response or better.
6, 7 and 9
 We undertook a phase 3 study to compare the efficacy and safety of 
pomalidomide plus low-dose dexamethasone with high-dose dexamethasone in patients with 
refractory or relapsed and refractory multiple myeloma. 
Methods 
Study design and participants 
MM-003 is an open-label, randomised phase 3 trial undertaken in 93 centres in Europe, Russia, 
Australia, Canada, and the USA (appendix). For inclusion in the trial, patients had to be refractory 
to their previous treatment;
10 and 11
 judged to have refractory or relapsed and refractory disease; had 
to have received at least two previous consecutive cycles of bortezomib and lenalidomide, alone or 
in combination; had adequate alkylator treatment (at least six cycles of alkylator treatment, or 
progressive disease after at least two cycles of alkylator treatment, or received alkylator treatment 
as part of a stem-cell transplant); and be older than 18 years. Patients must have failed (progressive 
disease on or before 60 days of treatment, progressive disease ≤6 months after achieving partial 
response, or intolerance to bortezomib) treatment with bortezomib or lenalidomide. Patients were 
classified on the basis of their disease status. They were thought to be refractory if they had 
progressed on or within 60 days of treatment with bortezomib and lenalidomide (and had developed 
progressive disease on or within 60 days after completing their last treatment) or relapsed and 
refractory if they had achieved at least a partial response to previous treatment with bortezomib or 
lenalidomide, or both, but progressed within 6 months (and had developed progressive disease on or 
within 60 days after completing their last treatment). Also included were patients who developed 
treatment intolerance after a minimum of two cycles of bortezomib and had developed progressive 
disease on or before 60 days after completing their last treatment. 
Patients were ineligible if they had previously received pomalidomide, had hypersensitivity to 
thalidomide, lenalidomide, or dexamethasone, or had resistance to high-dose dexamethasone 
(progressive disease on or within 60 days of the last dose used in their previous treatment). Patients 
were also considered ineligible if they had peripheral neuropathy of grade 2 or more; substantial 
cardiac disease (New York Heart Association Class III or IV, congestive heart failure, myocardial 
infarction on or within 12 months or unstable or poorly controlled angina); or showed any of the 
following laboratory abnormalities: absolute neutrophil count of less than 1 × 109 per L, platelet 
count of less than 75 × 109 per L (<30 × 109 per litre if ≥50% of bone marrow nucleated cells were 
plasma cells); creatinine clearance of less than 45 mL/min according to the Cockroft-Gault formula 
or 24 h urine collection; corrected serum calcium greater than 3·5 mmol/L; total bilirubin greater 
than 34·2 μmol/L; haemoglobin less than 80 g/L (4·9 mmol/L); or liver enzyme concentrations 
greater than three times the upper limit of normal. 
All patients provided written informed consent. The study was approved by institutional review 
boards or independent ethics committees at all participating centres and done in accordance with the 
Declaration of Helsinki and the International Conference on Harmonisation Guidelines on Good 
Clinical Practice. 
Randomisation and masking 
Patients were randomly assigned in a 2:1 ratio to pomalidomide plus low-dose dexamethasone or 
high-dose dexamethasone with a validated interactive voice and internet response system using a 
randomly permuted block within strata. The sponsor reviewed the enrolment and screening. 
Stratification factors were age (≤75 years vs >75 years), disease status (refractory vs relapsed and 
refractory vs bortezomib intolerant), and number of previous treatments (two vs three or more). 
Procedures 
Patients assigned to the pomalidomide plus low-dose dexamethasone group were given 28 day 
cycles of pomalidomide (4 mg/day on days 1–21, orally) plus low-dose dexamethasone (40 mg/day 
on days 1, 8, 15, and 22, orally). Patients assigned to the high-dose dexamethasone group were 
given 28 day cycles of high-dose dexamethasone (40 mg/day on days 1–4, 9–12, and 17–20). 
Dexamethasone dose was reduced to 20 mg/day in all patients older than 75 years. Treatment was 
continued until progressive disease or unacceptable toxicity occurred. Per protocol, pomalidomide 
was to be withheld for grade 4 and greater neutropenia, febrile neutropenia, and thrombocytopenia, 
grade 3 and greater venous thromboembolism, constipation, peripheral neuropathy, rash, and all 
other grade 3 or greater treatment-related adverse events, and also withheld for grade 2 or greater 
hypothyroidism or hyperthyroidism. On day 1 of the next treatment cycle, the dose of 
pomalidomide was to be reduced by 1 mg. Pomalidomide was to be discontinued in the event of 
grade 4 rash or rash with blistering, or grade 4 peripheral neuropathy. Dose modifications for 
dexamethasone were in accordance with the institutional guidelines. Appropriate concomitant 
treatments for adverse events were permitted. 
Follow-up for overall survival and new cancers (second primary malignancy) was planned to occur 
every 84 days for up to 5 years after randomisation. Patients progressing on high-dose 
dexamethasone could receive pomalidomide at the same dose, but without dexamethasone in a 
companion trial (MM-003C). Thromboprophylaxis was required for patients receiving 
pomalidomide or those at high risk of developing thrombosis. Choice of thromboprophylaxis and 
use of myeloid and erythroid growth factors was left to the physician's discretion. Severity of 
adverse events was graded in accordance with the National Cancer Institute Common Terminology 
Criteria for Adverse Events (version 4.0). Serious adverse events were defined as fatal, life-
threatening, requiring or prolonging hospitalisation, causing persistent or substantial disability or 
incapacity, involving a congenital anomaly or a birth defect, or constituting any other important 
medical event. 
Statistical analysis 
The primary endpoint was progression-free survival (PFS). The key secondary endpoint was overall 
survival. Other secondary endpoints were the overall response rate (the proportion of patients who 
achieved at least a partial response according to the International Myeloma Working Group 
criteria
12
 or European Group for Blood and Marrow Transplantation criteria for minor response 
only),
13
 time to progression, duration of response, safety, and quality of life. PFS and proportion of 
patients with an overall response presented in this report were based on investigator assessment of 
response and progressive disease in accordance with the International Myeloma Working Group 
criteria.
12
 Overall survival was to be tested only if the difference in PFS between treatment groups 
was significant. α was controlled at the 0·05 level with a two-sided test for both PFS and overall 
survival. Treatment effects were assessed in subgroups by stratification. Stratification per protocol 
was by age 75 years and younger versus more than 75 years; however, few data are presented 
because of the small number of patients. The subgroup analysis was by age 65 years and younger 
versus more than 65 years. Efficacy assessments were done in the intention-to-treat population (all 
randomly assigned patients) and safety assessment was done in the safety population (all patients 
who received at least one dose of study treatment). Relative dose intensity was calculated as the 
ratio of actual dose intensity to planned dose intensity (the ratio of cumulative dose to treatment 
duration). 
Target accrual was 426 patients (284 in the pomalidomide plus low-dose dexamethasone group and 
142 in the high-dose dexamethasone group) to have 242 PFS events (disease progression or death) 
with 85% power to detect a 50% improvement in median PFS (hazard ratio [HR] 1·5 for 
pomalidomide plus low-dose dexamethasone vs high-dose dexamethasone) at a two-sided 
significance level of 0·05. An interim analysis was planned for PFS using a group sequential 
procedure at 121 PFS events (50% information). If the futility boundary was crossed, the 
independent data monitoring committee could stop the trial. PFS was estimated with the Kaplan-
Meier product-limit method and a log-rank test (stratified by the three randomisation stratification 
variables) was used as the primary analytic method to compare survivorship functions between 
treatment groups. The final overall survival analysis was to be done after 212 patients from both 
treatment groups died during the study. An interim survival analysis was also planned at either the 
same time as the final PFS analysis or when 106 deaths (50% overall survival information) had 
occurred, whichever happened later. The O'Brien-Fleming boundary for superiority was used for 
the interim survival analysis and was based on the actual numbers of events (deaths). The α level 
for the final survival analysis was to be adjusted accordingly. Statistical analysis was done with the 
SAS software (version 9.2). 
This study is registered with ClinicalTrials.gov, number NCT01311687, and with EudraCT, number 
2010-019820-30. 
Role of the funding source 
The trial was designed by the investigators in collaboration with the manufacturers of 
pomalidomide (Celgene Corporation, Summit, NJ, USA). The study design was decided by the 
sponsor in collaboration with the study steering committee. All authors and the sponsor were 
involved in the data gathering, analysis, review, and interpretation, and writing of the report. The 
corresponding author had final responsibility for the decision to submit for publication. 
Results 
455 patients were enrolled in the MM-003 trial between March 18, 2011, and Aug 30, 2012; 302 
patients were randomly assigned to receive pomalidomide plus low-dose dexamethasone and 153 to 
receive high-dose dexamethasone (figure 1). At data cutoff (prespecified final PFS and interim 
overall survival, Sept 7, 2012), 267 PFS events had occurred (median follow-up 4·2 months [IQR 
2·0–7·1]). The interim survival analysis was done at this time, when 134 deaths had occurred. The 
independent data monitoring committee indicated that the trial met the primary endpoint of PFS and 
that the upper boundary for superior overall survival had been crossed even though 45 patients in 
the high-dose dexamethasone group crossed over and received pomalidomide. In accordance with 
the stopping rules, the committee recommended that patients assigned to high-dose dexamethasone 
who had not progressed should have access to pomalidomide (with or without dexamethasone). By 
March 1, 2013 (median follow-up 10·0 months [IQR 7·2–13·2]), the number of events was reached 
for the final overall survival analysis. Follow-up and analyses for the study are ongoing, but accrual 
is complete. Key results from Sept 7, 2012, and March 1, 2013 (updated PFS and final overall 
survival, response, and safety analyses) are presented. 
 Figure 1. Trial profile 
*Two patients excluded for more than one reason. 
Treatment groups were balanced for the baseline characteristics, with median time from diagnosis 
being similar in both treatment groups, and both groups having a median number of five previous 
treatments (table 1). Most patients were refractory to lenalidomide (95% in the pomalidomide plus 
low-dose dexamethasone group and 92% in the high-dose dexamethasone group; table 1). In the 
pomalidomide and low-dose dexamethasone group, 233 (81%) of 286 patients refractory to 
lenalidomide had progressed on lenalidomide at a dose of at least 25 mg/day. Most patients were 
also refractory to both lenalidomide and bortezomib (75% in the pomalidomide plus low-dose 
dexamethasone group and 74% in the high-dose dexamethasone group; table 1). Few patients were 
classified as having achieved a partial response or better and progressing within 6 months of 
completing their last previous treatment with lenalidomide or bortezomib-containing regimens (3% 
in each group; eight patients in the pomalidomide and low-dose dexamethasone group and five in 
the high-dose dexamethasone group), preventing meaningful subgroup analyses. 
 Table 1. Baseline characteristics of patients 
 
At the time of the updated PFS analysis, 242 (80%) of 302 patients in the pomalidomide plus low-
dose dexamethasone group and 142 (93%) of 153 in the high-dose dexamethasone group had 
discontinued study treatment (figure 1). Progressive disease was the most common reason for 
discontinuation: 163 patients (54%) in the pomalidomide plus low-dose dexamethasone group and 
92 patients (60%) in the high-dose dexamethasone group (figure 1). 
At the time of the final PFS and interim overall survival analyses (median follow-up 4·2 months 
[IQR 2·0–7·1]), both median PFS (3·8 months [95% CI 3·4–4·6] vs 1·9 months [1·9–2·1]; p<0·0001; 
HR 0·41 [0·32–0·53]; p<0·001) and overall survival (11·9 months [10·4–15·5] vs 7·8 months [6·4–
9·2]; 0·53 [0·37–0·74]; p=0·0002) were significantly longer in the pomalidomide plus low-dose 
dexamethasone group than in the high-dose dexamethasone group. 
At the time of the updated PFS and final overall survival analyses (median follow-up 10·0 months), 
the PFS data continued to show an advantage for pomalidomide plus low-dose dexamethasone 
compared with the high-dose dexamethasone group (4·0 months [95% CI 3·6–4·7] vs 1·9 months 
[1·9–2·2]; HR 0·48 [0·39–0·60]; p<0·0001; figure 2A). Median PFS was significantly longer with 
pomalidomide plus low-dose dexamethasone irrespective of previous treatment in the subgroup 
analyses ( figure 2B), including in patients refractory to lenalidomide (3·9 months [3·5–4·6] vs 1·9 
months [1·9–2·2]; p<0·0001), refractory to both bortezomib and lenalidomide (3·7 months [3·0–4·6] 
vs 2·0 months [1·9–2·2]; p<0·0001), intolerant to bortezomib (4·0 months [2·8–6·7] vs 2·0 months 
[1·9–3·7]; p=0·0073), with lenalidomide as their last treatment (4·6 months [3·5–6·0] vs 1·9 months 
[1·1–2·5]; p<0·0001), and with bortezomib as their last treatment (3·8 months [2·8–4·9] vs 1·9 
months [1·8–2·6]; p<0·0001; figure 2B). 
 Figure 2. Progression-free survival 
(A) Kaplan-Meier progression-free survival curves by treatment group in the ITT population. 
(B) Forest plot for progression-free survival for subgroup analysis by age, sex, and nature of 
previous treatments. Data are presented until the cutoff date (March 1, 2013). For (B) 
patients could be included in more than one subgroup. ITT=intention to treat. HR=hazard 
ratio. 
(B) In the final overall survival analysis, median overall survival was significantly longer in the 
pomalidomide plus low-dose dexamethasone group than in the high-dose dexamethasone group 
(12·7 months [95% CI 10·4–15·5] vs 8·1 months [6·9–10·8]; HR 0·74 [0·56–0·97]; p=0·0285; figure 
3A and 3B). Longer overall survival was also noted with pomalidomide plus low-dose 
dexamethasone versus high-dose dexamethasone in patients refractory to lenalidomide (12·7 
months [10·4–15·5] vs 8·0 months [6·4–10·1]; p=0·0234; figure 3B) and in patients with 
lenalidomide as their last therapy (12·3 months [9·8–16·4] vs 7·3 months [4·5–10·1] respectively; 
p=0·0097; figure 3B). No significant differences were noted between treatment groups for patients 
who were refractory to both lenalidomide and bortezomib (11·1 months [9·2–15·5] vs 7·7 months 
[5·4–10·1], p=0·0957), were intolerant to bortezomib (15·5 months [11·1–19·2] vs 8·6 months [5·4–
not reached], p=0·1405), or had last received bortezomib (13·1 months [10·4–16·4] vs 12·3 months 
[6·2–not reached], p=0·5457; figure 3B). Statistical analysis showed there was no significant 
difference in PFS or overall survival between the sexes. 76 (50%) of 153 patients in the high-dose 
dexamethasone group had received pomalidomide at a median follow-up of 10·0 months 
compared with 45 (29%) at a median follow-up of 4·2 months (IQR 2·0–7·1). Based on our data, we 
estimate that all patients in the high-dose dexamethasone group would have received 
pomalidomide after 16 months of follow-up ( figure 4). 
 
 Figure 3. Overall survival 
(A) Kaplan-Meier overall survival curves by treatment group in the ITT population. (B) Forest 
plot for overall survival for subgroup analysis by age, sex, and nature of previous 
treatments. Data are presented until the cutoff date (March 1, 2013). For (B) patients could 
be included in more than one subgroup. ITT=intention to treat. HR=hazard ratio. 
 Figure 4. Patients on high-dose dexamethasone receiving pomalidomide as salvage 
treatment 
 
Time to progression was longer in the pomalidomide plus low-dose dexamethasone group (median 4·7 
months [95% CI 4·0–6·0] vs 2·1 months [1·9–2·5], respectively; HR 0·46 [0·36–0·59]; p<0·0001). Overall 
response rate after a median follow-up of 10·0 months was documented in 31% of 302 patients in the 
pomalidomide plus low-dose dexamethasone group versus 10% of 153 in the high-dose dexamethasone 
group (odds ratio [OR] 4·22 [2·35–7·58]; p<0·0001; table 2). In patients with at least partial response, 
median response duration was 7·0 months (5·8–9·0) and 6·1 months (1·4–8·5), respectively (HR 0·52 [0·25–
1·05]; p=0·0631; table 2). In patients who were refractory to lenalidomide, overall responses were noted in 
30% of those in the pomalidomide plus low-dose dexamethasone group and 9% in the high-dose 
dexamethasone group (OR 4·16 [2·23–7·77]; p<0·0001; table 3), 31% and 13%, respectively, in patients who 
were intolerant to bortezomib (3·01 [0·77–11·82]; p=0·1423]; table 3); 28% and 12%, respectively, in 
patients who were refractory to both bortezomib and lenalidomide (3·06 [1·60–5·84]; p=0·0003; table 3); 
33% and 6%, respectively, in patients with lenalidomide as their last treatment (7·53 [2·15–26·35]; 
p=0·0003; table 3), and 34% and 12%, respectively, in patients with bortezomib as their last treatment (3·75 
[1·65–8·53]; p=0·0011; table 3). Median duration of response in patients who were refractory to 
lenalidomide was 7·0 months (5·8–8·8) in the pomalidomide plus low-dose dexamethasone group and 7·4 
months (1·4–9·4) in the high-dose dexamethasone group (p=0·3322). In patients who were refractory to 
both bortezomib and lenalidomide, duration of response was 7·0 months (5·8–9·0) in the pomalidomide 
plus low-dose dexamethasone group and 7·4 months (1·4–9·4) in the high-dose dexamethasone group 
(p=0·3149). PFS was 8·0 months (7·4–9·4) in patients achieving a minor response or better with 
pomalidomide plus low-dose dexamethasone and 9·5 months (5·3–33·4) in patients receiving high-dose 
dexamethasone (p=0·251). 
Table 2. Best response based on investigator's assessment
*
 as of data cutoff (March 1, 2013) 
 
 
Table 3. Patients with an overall response based on investigator's assessment by subgroup 
analyses, as of data cutoff (March 1, 2013) 
 
 
Median PFS was similar in patients 65 years and younger and those older than 65 years receiving 
pomalidomide plus low-dose dexamethasone (3·9 months [95% CI 3·48–5·61] and 4·0 months 
[3·09–4·87], respectively), as were median overall survival (12·7 months [10·08–16·41] and 13·1 
months [9·78–15·53], respectively), overall response rate (52 [31%] of 167 and 43 [32%] of 135, 
respectively), and median duration of response (7·1 months [5·61–13·08] and 6·6 months [5·63–
9·00], respectively). Results in the 24 patients older than 75 years were also similar, but statistical 
analyses were limited by the small number of patients (data not shown). 
The safety population (all patients receiving at least one dose of pomalidomide) consisted of 300 
patients in the pomalidomide plus low-dose dexamethasone group and 150 in the high-dose 
dexamethasone group. In the pomalidomide plus low-dose dexamethasone group, 201 (67%) of 300 
patients required pomalidomide dose interruptions and 82 (27%) required pomalidomide dose 
reductions; the median relative dose intensity was 0·9 (range 0·3–1·3). In the high-dose 
dexamethasone group, 42 (28%) of 150 patients had dose interruptions and 48 (32%) had dose 
reductions; median relative dose intensity was 1·0 (0·3–2·0). Few patients discontinued treatment 
because of treatment-related adverse events (11 [4%] of 300 patients in the pomalidomide plus low-
dose dexamethasone group and nine [6%] of 150 patients in the high-dose dexamethasone group). 
Treatment-related adverse events are shown in table 4. The pattern of adverse events was generally 
similar across subgroups based on risk stratification factors (data not shown). The most common 
grade 3–4 haematological adverse events in the pomalidomide plus low-dose dexamethasone and 
high-dose dexamethasone groups were neutropenia (143 [48%] of 300 vs 24 [16%] of 150, 
respectively), anaemia (99 [33%] vs 55 [37%], respectively), and thrombocytopenia (67 [22%] vs 
39 [26%], respectively). Baseline characteristics of patients with and without treatment-emergent 
grade 3–4 neutropenia were similar (data not shown). Grade 3–4 non-haematological adverse events 
in the pomalidomide plus low-dose dexamethasone and high-dose dexamethasone groups included 
pneumonia (38 [13%] vs 12 [8%], respectively), bone pain (21 [7%] vs seven [5%], respectively), 
and fatigue (16 [5%] vs nine [6%], respectively). Incidence of pneumonia (any grade) was similar 
in the two groups (46 [15%] vs 16 [11%]; table 4). Occurrence of neutropenia did not seem to affect 
the incidence of infections, and grade 3–4 infections occurred in 91 (30%) patients in the 
pomalidomide plus low-dose dexamethasone group and 36 (24%) in the high-dose dexamethasone 
group. Most infections (any grade) occurred in the absence of neutropenia (133 [66%] of 203 vs 68 
[86%] of 79, respectively). In the pomalidomide plus low-dose dexamethasone group the incidence 
of grade 3 or worse febrile neutropenia (29 [10%]) was fairly low; however, the rate was lower in 
the high-dose dexamethasone group (one [<1%] grade <3). The rate of pomalidomide 
discontinuation due to infection (seven [2%]) was low (data not shown). Granulocyte colony-
stimulating factor was used in 130 (43%) patients in the pomalidomide plus low-dose 
dexamethasone group and 19 (13%) in the high-dose dexamethasone group. 268 (89%) and 127 
(85%) patients, respectively, used anti-infective agents (antibiotics, antifungal drugs, and antiviral 
drugs). 148 (49%) patients in the pomalidomide plus low-dose dexamethasone group and 79 (53%) 
in the high-dose dexamethasone group required red blood-cell transfusions, and 61 (20%) and 32 
(21%) patients, respectively, required platelet transfusions. 
 
Table 4. Summary of the most commonly reported adverse events occurring in more than 
10% of the safety population 
  
46 (15%) of 300 patients in the pomalidomide plus low-dose dexamethasone group and 16 (11%) of 
150 in the high-dose dexamethasone group had peripheral neuropathy of any grade; four (1%) 
patients in the pomalidomide plus low-dose dexamethasone group and two (1%) in the high-dose 
dexamethasone group developed grade 3 or greater neuropathy. With thromboprophylaxis, deep-
vein thrombosis and pulmonary embolism were infrequent in the pomalidomide plus low-dose 
dexamethasone and high-dose dexamethasone groups (any grade, six [2%] of 300 vs two [1%] of 
150 patients, respectively; grade 3–4, three [1%] vs zero, respectively). The median time to onset of 
deep-vein thrombosis or pulmonary embolism was 4·0 months (range 1·0–6·2) in the pomalidomide 
plus low-dose dexamethasone group and 2·3 months (1·1–3·5) in the high-dose dexamethasone 
group. So far, one patient in each group has died of deep-vein thrombosis or pulmonary embolism 
as a consequence of disease progression. Four patients in the pomalidomide plus low-dose 
dexamethasone group and one in the high-dose dexamethasone group developed a second primary 
malignancy. Two patients in the pomalidomide plus low-dose dexamethasone group had invasive 
solid cancers, and two patients in this group and one in the high-dose dexamethasone group had 
non-invasive (basal-cell) skin cancers. 
Serious adverse events (defined as grade 5, requiring hospitalisation, or resulting in disability or 
incapacity) were reported in 183 (61%) of 300 patients in the pomalidomide plus low-dose 
dexamethasone group and 80 (53%) of 150 patients in high-dose dexamethasone group; 144 (48%) 
and 80 (53%) patients died, respectively. The most common cause of death was progression of 
multiple myeloma, which accounted for 98 (68%) deaths in the pomalidomide plus low-dose 
dexamethasone and 51 (64%) in the high-dose dexamethasone groups. Overall, infection was the 
second most common cause of death, but accounted for more deaths in the high-dose 
dexamethasone group than in the pomalidomide plus low-dose dexamethasone group (14 [10%] of 
144 deaths vs 15 [19%] of 80). There were 11 (4%) treatment-related deaths in the pomalidomide 
plus low-dose dexamethasone group (eight cases of infections and infestations, two cases of 
multiorgan failure or sudden death, and one nervous system disorder) and seven (5%) in the high-
dose dexamethasone group (all infections and infestations). 
Discussion 
Pomalidomide plus low-dose dexamethasone resulted in significantly longer PFS and overall 
survival, and a greater number of responses compared with high-dose dexamethasone in patients 
with advanced refractory or relapsed and refractory multiple myeloma (panel). 
 
Panel.  
Research in context 
Systematic review 
We undertook a systematic search of PubMed, ClinicalTrials.gov, and recent (2010–11) international 
congresses (American Society of Hematology, American Society of Clinical Oncology, and European 
Hematology Association) using the search terms “multiple myeloma”, “relapsed and/or refractory”, 
“refractory myeloma”, and “salvage therapy”. From the search, we noted that patients with relapsed or 
refractory multiple myeloma in whom treatment with bortezomib and lenalidomide had been 
exhausted had few treatment options and poor outcomes.
1
 The safety and efficacy of pomalidomide 4 
mg/day on days 1–21 of each 28 day cycle in combination with low-dose dexamethasone in heavily 
pretreated patients had been shown in two phase 2 trials.
5 and 6
 To our knowledge, this study is the first 
phase 3 trial designed to compare the efficacy and safety of pomalidomide plus low-dose 
dexamethasone with high-dose dexamethasone, which was chosen as the comparator for registration 
trials of bortezomib and lenalidomide.
14, 15 and 16
 
Interpretation 
Pomalidomide plus low-dose dexamethasone significantly prolonged median progression-free survival 
and overall survival compared with high-dose dexamethasone, even though 50% of patients assigned 
to high-dose dexamethasone had received pomalidomide at the time of the final analysis. With 
appropriate dose modifications, the safety profile of the combination was predictable, manageable, and 
generally well-tolerated in this heavily pretreated population. Few patients discontinued treatment 
because of treatment-related adverse events. Based on our results, pomalidomide plus low-dose 
dexamethasone could be a treatment option for patients with advanced refractory or relapsed and 
refractory multiple myeloma in whom treatment with bortezomib and lenalidomide has been 
unsuccessful. 
To our knowledge, MM-003 is the first phase 3 study of pomalidomide in patients with advanced 
refractory or relapsed and refractory multiple myeloma in whom treatment with bortezomib and 
lenalidomide has been exhausted. At the time this study was initiated, there was no standard of care 
for these patients, and high-dose dexamethasone was a commonly used rescue treatment for heavily 
pretreated patients. Therefore, the study steering committee chose high-dose dexamethasone as the 
comparator to isolate the effects of pomalidomide. In previous registration studies of 
lenalidomide
15 and 16
 and bortezomib
17
 in patients with relapsed or refractory multiple myeloma, 
high-dose dexamethasone was also used as a comparator. In these studies, overall response rates to 
high-dose dexamethasone ranged from 18% to 24%, and median time to progression was 3·5–4·7 
months in patients who had received at least one previous treatment. Patients in our study had 
received many more previous treatments than did those in the lenalidomide and bortezomib 
registration studies. The median overall survival of 8·1 months in the control group is consistent 
with the expected median 9 months in historical controls.
1
 Moreover, our findings confirm those of 
previous phase 2 studies of pomalidomide for advanced myeloma.
6, 7 and 18
 Altogether, these findings 
suggest that pomalidomide plus low-dose dexamethasone could be a beneficial treatment option for 
this patient population. Other pomalidomide-based combination treatments show encouraging 
efficacy, with 30–54% of patients achieving an overall response, and are being assessed in clinical 
trials.
19, 20, 21, 22, 23 and 24
 
Only two drugs (pomalidomide and carfilzomib) have been approved for the treatment of patients in 
whom use of bortezomib and lenalidomide has been exhausted. There are few options for salvage 
treatment, which are limited to rechallenge with a previously used treatment (alone, or in 
combination with corticosteroids or other novel agents), use of older drugs (eg, thalidomide, 
melphalan, vincristine, doxorubicin, and carmustine), or enrolment in a clinical trial.
1
 Outcomes 
with subsequent treatment using standard therapies are characterised by short durations of response 
and increasing drug resistance.
25
 Therefore, there is a need for effective antimyeloma treatments for 
patients with advanced multiple myeloma. 
Carfilzomib has been approved by the US Food and Drug Administration for patients with relapsed 
or refractory multiple myeloma who have received at least two previous treatments, including 
bortezomib and an immunomodulatory agent.
26
 In a subpopulation of 169 patients refractory to both 
bortezomib and lenalidomide, carfilzomib monotherapy resulted in a response rate of 15% with a 
median overall survival of 11·9 months.
27
 Studies to assess the efficacy of carfilzomib in 
combination with lenalidomide and low-dose dexamethasone for refractory or relapsed and 
refractory multiple myeloma (NCT01080391)
28
 and higher doses of carfilzomib in combination 
with dexamethasone are underway.
29
 However, unlike pomalidomide, carfilzomib is not an oral 
drug. 
Our results showed longer overall survival than PFS in patients receiving pomalidomide plus low-
dose dexamethasone. This finding is similar to the results of other studies of patients with refractory 
or relapsed and refractory multiple myeloma,
15, 16, 17, 30 and 31
 and might be explained by progression 
in advanced disease being biochemical, with clinical manifestation of relapse not occurring until 
months later. The prolonged overall survival might also indicate the availability of other effective 
salvage treatments; patients progressing after treatment with pomalidomide plus low-dose 
dexamethasone might be in better overall health than those who did not receive this treatment
32
 and, 
therefore, able to tolerate or benefit from regimens that would otherwise not have been an option. 
Adverse events in this trial were consistent with the safety profile of pomalidomide plus low-dose 
dexamethasone,
6 and 7
 and other immunomodulatory agents for patients with refractory or relapsed 
and refractory multiple myeloma.
15 and 16
 The main grade 3–4 adverse event was neutropenia, and 
the incidence of febrile neutropenia was low. In this study, most grade 3–4 infections were 
unrelated to neutropenia. The incidence of grade 3–4 peripheral neuropathy and deep-vein 
thrombosis and pulmonary embolism (with thromboprophylaxis) was low (≤1% in each of the 
treatment groups). Discontinuation of pomalidomide plus low-dose dexamethasone because of 
adverse events was uncommon (9%), suggesting that the combination was generally well-tolerated. 
Cross-sectional, longitudinal, and time-to-worsening analyses for clinically relevant European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 domains 
(global health status, physical functioning, emotional functioning, fatigue, and pain) are planned 
and will be published in the future. 
A limitation of this study is its open-label design. Additionally, the unmasked nature of the study 
may have affected the updated PFS analysis in favour of the high-dose dexamethasone group 
because nine patients crossed over before progressive disease. Furthermore, the crossover of 
patients receiving high-dose dexamethasone without progressive disease to receive pomalidomide 
unblinded is expected to have reduced the magnitude of the difference in overall survival between 
the treatment groups from the interim to the final overall survival analysis. 
In conclusion, pomalidomide plus low-dose dexamethasone significantly improved PFS, overall 
survival, and proportion of patients showing overall response compared with high-dose 
dexamethasone in patients with refractory or relapsed and refractory multiple myeloma, including 
patients with disease refractory to both bortezomib and lenalidomide. Studies of different 
combinations including pomalidomide in patients with refractory or relapsed and refractory 
multiple myeloma have shown promising results, and the enhanced effects with pomalidomide 
combinations should be further investigated. Based on these findings and the results of previous 
trials, pomalidomide plus low-dose dexamethasone could be a new treatment option for patients 
with advanced refractory or relapsed and refractory multiple myeloma. 
Contributors 
JSM, KW, PM, ML, KS, MD, LK, HG, AB, AO, AA, CC, MC, LG, VI, JM-L, AB, AP, SS, PS, 
and MD (senior author) were principal investigators and involved in the data gathering and 
interpretation. JSM, XY, LS, CJ, and MZ contributed to the statistical analyses and generation of 
tables and figures. JSM, XY, LS, CJ, MZ, and MD were involved in the development and writing of 
the report. All authors reviewed and approved the submitted report. 
Conflicts of interest 
JSM has had a consultancy or advisory role, and has received honoraria from Celgene Corporation, 
Jansen, Millennium, Novartis, and Onyx. KW has had a consultancy or advisory role and has 
received honoraria from Celgene Corporation. PM has had a consultancy or advisory role and has 
received honoraria from Celgene Corporation, Millennium, and Janssen. ML has received research 
funding from Celgene Corporation. KS has had a consultancy or advisory role, received honoraria, 
and has received research funding from Celgene Corporation and Janssen. MD and AA have had a 
consultancy or advisory role and received research funding from Celgene Corporation and Janssen. 
LK has had a consultancy or advisory role and provided export testimony for Celgene Corporation, 
and received honoraria and other remuneration from Celgene Corporation and Janssen. HG has had 
a consultancy or advisory role, received honoraria and received research funding from Celgene 
Corporation and Janssen. AO has had a consultancy and advisory role for Celgene Corporation and 
Janssen. CC has had a consultancy or advisory role, received honoraria, and received research 
funding from Celgene Corporation. MC has had a consultancy or advisory role and has received 
honoraria from Celgene Corporation, Janssen, and Millennium. JM-L has received honoraria and 
research funding from Celgene Corporation. AB has received research funding from Celgene 
Corporation. AP has received honoraria and was a member of the board of an advisory committee 
for Celgene Corporation and Janssen-Cilag, and received honoraria from OrthoBiotech. SS has had 
a consultancy role and received honoraria from Celgene Corporation. PS has received honoraria and 
funding from Celgene Corporation, Janssen, and Onyx. XY, LS, CJ, and MZ are employed and 
have equity ownership with Celgene Corporation. MD has had a consultancy or advisory role for 
Celgene Corporation and Ortho Biotech, and has received research funding from Genesis Pharma. 
The other authors declare that they have no conflicts of interest. 
Acknowledgements 
Acknowledgments 
This research was funded by Celgene Corporation. We thank the patients who volunteered to 
participate in this study and staff members at the study sites who cared for them, and the 
representatives of the sponsors who were involved in data gathering and analyses. We thank Eva 
Polk and Anna Georgieva from Excerpta Medica, for their writing assistance, which was funded by 
Celgene Corporation. 
References 
References 
1. SK Kumar, JH Lee, JJ Lahuerta, et al. 
Risk of progression and survival in multiple myeloma relapsing after therapy with 
IMiDs and bortezomib therapy: a multicentre International Myeloma Working Group 
study 
Leukemia, 26 (2012), pp. 149–157 
2. H Quach, D Ritchie, AK Stewart, et al. 
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma 
Leukemia, 24 (2010), pp. 22–32 
3. J Matous, DSD Siegel, HK Duong, et al. 
MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus lowdose 
dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) 
patients with renal impairment (RI) 
J Clin Oncol, 31 (suppl) (2013) abstr 8585. 
4. SA Schey, P Fields, JB Bartlett, et al. 
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or 
refractory multiple myeloma 
J Clin Oncol, 22 (2004), pp. 3269–3276 
 
5. MJ Streetly, K Gyertson, Y Daniel, JB Zeldis, M Kazmi, SA Schey 
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events 
and evidence of in vivo immunomodulation 
Br J Haematol, 141 (2008), pp. 41–51 
6. S Jagannath, CC Hofmeister, DS Siegel, et al. 
Pomalidomide (POM) with low-dose dexamethasone (LoDex) in patients (pts) with 
relapsed and refractory multiple myeloma who have received prior therapy with 
lenalidomide (LEN) and bortezomib (BORT): updated phase 2 results and age subgroup 
analysis 
Blood, 120 (2012), p. 450 (abstr). 
7. X Leleu, M Attal, B Arnulf, et al. 
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib 
and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 
2009-02 
Blood, 121 (2013), pp. 1968–1975 
8. PG Richardson, D Siegel, R Baz, et al. 
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory 
multiple myeloma who have received lenalidomide and bortezomib 
Blood, 121 (2013), pp. 1961–1967 
9. MQ Lacy, SK Kumar, BR LaPlant, et al. 
Pomalidomide plus low-dose dexamethasone (Pom/Dex) in relapsed myeloma: long 
term follow up and factors predicting outcome in 345 patients 
Blood, 120 (2012), p. 201 (abstr). 
10. PG Richardson, B Barlogie, J Berenson, et al. 
A phase 2 study of bortezomib in relapsed, refractory myeloma 
N Engl J Med, 348 (2003), pp. 2609–2617 
11. KC Anderson, RA Kyle, SV Rajkumar, et al. 
Clinically relevant end points and new drug approvals for myeloma 
Leukemia, 22 (2008), pp. 231–239 
 
12. BG Durie, JL Harousseau, JS Miguel, et al. 
International uniform response criteria for multiple myeloma 
Leukemia, 20 (2006), pp. 1467–1473 
13. J Bladé, D Samson, D Reece, et al. 
Criteria for evaluating disease response and progression in patients with multiple 
myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. 
Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow 
Transplant 
Br J Haematol, 102 (1998), pp. 1115–1123 
14. EM Ocio, D Fernández-Lázaro, L San-Segundo, et al. 
Reversibility of the resistance to lenalidomide and pomalidomide and absence of cross-
resistance in a murine model of MM 
Blood, 118 (2011), p. 134 (abstr). 
15. DM Weber, C Chen, R Niesvizky, et al. 
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America 
N Engl J Med, 357 (2007), pp. 2133–2142 
16. M Dimopoulos, A Spencer, M Attal, et al. 
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma 
N Engl J Med, 357 (2007), pp. 2123–2132 
17. PG Richardson, P Sonneveld, MW Schuster, et al. 
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma 
N Engl J Med, 352 (2005), pp. 2487–2498 
18. R Vij, PG Richardson, S Jagannath, et al. 
Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients 
(pts) with relapsed/refractory multiple myeloma (RRMM): outcomes in pts refractory to 
lenalidomide (LEN) and/or bortezomib (BORT) 
Proc Am Soc Clin Oncol, 30 (suppl) (2012), p. 8016 (abstr). 
19. A Palumbo, A Larocca, V Montefusco, et al. 
Pomalidomide cyclophosphamide and prednisone (PCP) treatment for 
relapsed/refractory multiple myeloma 
Blood, 120 (2012), p. 446 (abstr). 
20. R Baz, KH Shain, M Alsina, et al. 
Oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone 
for relapsed and refractory myeloma: report of the dose escalation cohort 
Blood, 120 (2012), p. 4062 (abstr). 
21. JR Berenson, JD Hilger, LM Klein, et al. 
A phase 1/2 study of pomalidomide, dexamethasone and pegylated liposomal 
doxorubicin for patients with relapsed/refractory multiple myeloma 
Blood, 120 (2012), p. 2979 (abstr). 
22. TM Mark, A Boyer, AC Rossi, et al. 
ClaPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory 
multiple myeloma 
Blood, 120 (2012), p. 77 (abstr). 
23. PG Richardson, CC Hofmeister, S Siegel, et al. 
MM-005: a phase 1, multicenter, open-label, dose-escalation study to determine the 
maximum tolerated dose for the combination of pomalidomide, bortezomib, and low-
dose dexamethasone in subjects with relapsed or refractory multiple myeloma 
Blood, 120 (2012), p. 727 (abstr). 
24. JJ Shah, EA Stadtmauer, R Abonour, et al. 
A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone 
(Car-Pom-d) in patients with relapsed/refractory multiple myeloma 
Blood, 120 (2012), p. 74 (abstr). 
25. KC Anderson, RA Kyle, SV Rajkumar, et al. 
Clinically relevant end points and new drug approvals for myeloma 
Leukemia, 22 (2008), pp. 231–239 
26. US Food and Drug Administration (FDA) 
Approved drugs–Carfilzomib 
www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm312945.htm (accessed 
July 1, 2013). 
27. DS Siegel, T Martin, M Wang, et al. 
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed 
and refractory multiple myeloma 
Blood, 120 (2012), pp. 2817–2825 
28. P Moreau, AP Palumbo, AK Stewart, et al. 
A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), 
lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with 
relapsed multiple myeloma (MM) 
Proc Am Soc Clin Oncol, 29 (suppl) (2011), p. TPS225 
29. AZ Badros, KP Papadopoulos, N Zojwalla, et al. 
A phase 1b study of 30-minute infusion carfilzomib 20/45 and 20/56 mg/m
2
 plus 40 mg 
weekly dexamethasone in patients with relapsed and/or refractory (r/r) multiple 
myeloma 
Blood, 120 (2012), p. 21 (abstr). 
30. DS Siegel, MA Dimopoulos, SS Yoon, et al. 
Vantage 095: Vorinostat in combination with bortezomib in salvage multiple myeloma 
patients: final study results of a global phase 2b trial 
Blood, 118 (2011), p. 480 (abstr). 
31. PG Richardson, M Alsina, D Weber, et al. 
PANORAMA 2: panobinostat combined with bortezomib and dexamethasone in patients 
with relapsed and bortezomib-refractory multiple myeloma 
Blood, 120 (2012), p. 1852 (abstr). 
32. J San Miguel, KC Weisel, P Moreau, et al. 
Quality of life improvements for pomalidomide + low-dose dexamethasone (POM + 
LoDEX) in relapsed and refractory multiple myeloma 
Haematologica, 98 (suppl 1) (2013), p. 430 (abstr) 
 
 
